第一作者单位：[1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan, Peoples R China[2]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hubei Clin Res Ctr Hepat Surg, Wuhan, Peoples R China[3]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hubei Key Lab Hepatopancreatobiliary Dis, 1095 Jiefang Ave, Wuhan 430030, Peoples R China
通讯作者：
通讯机构：[1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan, Peoples R China[2]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hubei Clin Res Ctr Hepat Surg, Wuhan, Peoples R China[3]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hubei Key Lab Hepatopancreatobiliary Dis, 1095 Jiefang Ave, Wuhan 430030, Peoples R China[*1]Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.Hubei Clinical Research Center for Hepatic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan 430030, China
推荐引用方式(GB/T 7714)：
Zhang Zunyi,Zhang Wei.Conversion therapy for advanced cholangiocarcinoma in the era of molecular targeted therapy and immune therapy[J].HEPATOBILIARY SURGERY AND NUTRITION.2023,12(5):772-775.doi:10.21037/hbsn-23-352.
APA：
Zhang, Zunyi&Zhang, Wei.(2023).Conversion therapy for advanced cholangiocarcinoma in the era of molecular targeted therapy and immune therapy.HEPATOBILIARY SURGERY AND NUTRITION,12,(5)
MLA：
Zhang, Zunyi,et al."Conversion therapy for advanced cholangiocarcinoma in the era of molecular targeted therapy and immune therapy".HEPATOBILIARY SURGERY AND NUTRITION 12..5(2023):772-775
医学